peptide receptor radionuclide therapy

You have access
Prediction of ¹⁷⁷Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, Carlos Artigas, Camille Van Bogaert, Clémentine Marin, Rachele Danieli, Amelie Deleporte, Simona Picchia, Konstantinos Stathopoulos, Christiane Jungels, Bruno Vanderlinden, Marianne Paesmans, Lieveke Ameye, Gabriela Critchi, Loubna Taraji-Schiltz, Chloe Velghe, Zéna Wimana, Maria Bali, Alain Hendlisz, Patrick Flamen and Ioannis Karfis

Journal of Nuclear Medicine February 1, 2024, 65 (2) 236-244; DOI: https://doi.org/10.2967/jnumed.123.265987
You have access
Impact of Single-Time-Point Estimates of ¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles
Alexandre Chicheportiche, Moshe Sason, Mahmoud Zidan, Jeremy Godefroy, Yodphat Krausz, David J. Gross, Simona Grozinsky-Glasberg and Simona Ben-Haim

Journal of Nuclear Medicine October 1, 2023, 64 (10) 1610-1616; DOI: https://doi.org/10.2967/jnumed.122.264923
You have access
Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden
Denise A. Gococo-Benore, Justin Kuhlman, Ephraim E. Parent, Akash Sharma, Joseph Accurso, Ming Yang, Ayse Tuba Kendi, Geoff Johnson, Mohamad Bassam Sonbol, Timothy Hobday, Thorvardur R. Halfdanarson and Jason Starr

Journal of Nuclear Medicine June 1, 2023, 64 (6) 880-884; DOI: https://doi.org/10.2967/jnumed.122.264533
You have access
Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumor Patients
Noémie S. Minczeles, Wouter W. de Herder, Richard A. Feelders, Frederik A. Verburg, Johannes Hofland and Tessa Brabander

Journal of Nuclear Medicine January 1, 2023, 64 (1) 40-46; DOI: https://doi.org/10.2967/jnumed.122.263856
You have access
Safety of Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
Shahad Alsadik, Gopinath Gnanasegaran, Luohai Chen, Dalvinder Mandair, Christos Toumpanakis, Martyn Caplin and Shaunak Navalkissoor

Journal of Nuclear Medicine October 1, 2022, 63 (10) 1503-1508; DOI: https://doi.org/10.2967/jnumed.121.263056
You have access
Efficacy and Safety of ¹⁷⁷Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
Lamiaa Zidan, Amir Iravani, Kira Oleinikov, Simona Ben-Haim, David J. Gross, Amichay Meirovitz, Ophra Maimon, Tim Akhurst, Michael Michael, Rodney J. Hicks, Simona Grozinsky-Glasberg and Grace Kong

Journal of Nuclear Medicine February 1, 2022, 63 (2) 218-225; DOI: https://doi.org/10.2967/jnumed.120.260760
Open Access
Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival
Giulia Tamborino, Julie Nonnekens, Marijke De Saint-Hubert, Lara Struelens, Danny Feijtel, Marion de Jong and Mark W. Konijnenberg

Journal of Nuclear Medicine January 1, 2022, 63 (1) 100-107; DOI: https://doi.org/10.2967/jnumed.121.262122
You have access
Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant ¹⁷⁷Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors
Rahul V. Parghane, Manish Bhandare, Vikram Chaudhari, Vikas Ostwal, Anant Ramaswamy, Sanjay Talole, Shailesh V. Shrikhande and Sandip Basu

Journal of Nuclear Medicine November 1, 2021, 62 (11) 1558-1563; DOI: https://doi.org/10.2967/jnumed.120.258772
You have access
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects
Sonya Park, Ashwin Singh Parihar, Lisa Bodei, Thomas A. Hope, Nadine Mallak, Corina Millo, Kalpna Prasad, Don Wilson, Katherine Zukotynski and Erik Mittra

Journal of Nuclear Medicine October 1, 2021, 62 (10) 1323-1329; DOI: https://doi.org/10.2967/jnumed.120.251512
You have access
Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma
Jorge A. Carrasquillo, Clara C. Chen, Abhishek Jha, Karel Pacak, Daniel A. Pryma and Frank I. Lin

Journal of Nuclear Medicine September 1, 2021, 62 (9) 1192-1199; DOI: https://doi.org/10.2967/jnumed.120.259697

Main menu

User menu

Search

peptide receptor radionuclide therapy

Pages